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The general synthetic strategy towards water-soluble biodegradable drug carriers and the properties that they must have are dis-
cussed. The syntheses of water-soluble biodegradable copolymers of lysine and aspartic acid as potential drug-delivering devices,
having amine-functionalised side chains are then described. Covalent anchoring of carboxylic acid derivatives of the antineo-
plastic ferrocene and photodynamically active phthalocyanine moieties to the amine-containing drug carrier copolymers under
mild coupling conditions has been achieved utilising the coupling reagent O-benzotriazolyl-N,N,N ,N -tetramethyluronium hex-
aﬂuorophosphate to promote formation of the biodegradable amide bond. Even though the parent antineoplastic ferrocene and
phthalocyanine derivatives are themselves insoluble in water at pH < 7, the new carrier-drug conjugates that were obtained are
well water-soluble.
Copyright © 2008 M. David Maree et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
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1. INTRODUCTION
In accordance with the goals of this special issue of metal-
baseddrugs,thisarticledeemstofulﬁlateachingandguiding
role in new anticancer drug research. We hope it will spawn
new ideas and new research in the ﬁeld of anticancer therapy.
In what follows, we ﬁrst create an understanding of why new
anticancer drugs are vigorously searched for by highlighting
some of the problems associated with a typical chemother-
apeutic agent, cisplatin. One possible way to minimise the
negativesideeﬀectsassociatedwithchemotherapeuticagents
is to make use of a synthetic polymeric drug delivery sys-
tem. We explain how such systems may signiﬁcantly enhance
the therapeutic eﬀectiveness of chemotherapeutic agents and
highlight some of the structural features they must have. We
then develop a general synthetic strategy an experimental
chemist may follow to actually synthesise a polymeric drug
delivering device and proceed to visualise this strategy utilis-
ing a literature example. The need for certain structural fea-
tures in a delivering device is then motivated by a discussion
of the biological mechanism of cell uptake and drug release
from the drug carrying device. In conclusion, the synthesis
and characterisation of a new example of a polymeric drug
delivery system derived from aspartic acid and lysine is pre-
sented.
2. PROBLEMS ASSOCIATED WITH
CHEMOTHERAPEUTIC DRUGS
Many potentially good pharmaceutical agents are either dose
limited, or excluded from use in clinical therapy due to in-
solubility in an aqueous medium, or because of the many se-
vere side eﬀects that they may exhibit. As far as cisplatin, the
most successful metal-containing chemotherapeutic drug of
recent times [1], is concerned, these side eﬀects include inter
alia:
(a) poor aqueous solubility;
(b) intensive damage to the linings of the intestines, which
leads to the loss of appetite (anorexia) and eventually
starving in the case of mice and rats [2];
(c) severe nausea, vomiting, and audio toxicity [3];2 Metal-Based Drugs
(d) high toxicity towards the kidneys and bone marrow
[4];
(e) being a moderate carcinogen itself. It can induce lung
cancer, skin papillomas, and other carcinomas [5].
In general, most if not all chemotherapeutic drug side eﬀects
are due to their general inability to diﬀerentiate between dis-
eased and healthy cells [6].
Even if a synthetic chemotherapeutic drug has few side
eﬀects, it does not imply success in clinical use. One must re-
alize that chemotherapeutic agents usually are poisons, or at
theveryleast,theyareforeigntothebody.Thedefencemech-
anism of the body, the reticuloendothelial system, recognizes
t h e ma ss u c ha n dt r i e st or e m o v et h e ma sf a s ta sp o s s i b l e .
A fast excretion rate from the body often proves detrimen-
tal to chemotherapy. Cisplatin, for example, is eliminated
from the body in a biphasic excretion mechanism in such
a way that 50% of the initial administered dose is excreted
within 20 hours [7]. After 110 hours, 70% of the initial ad-
ministered amount of drug is removed from the body by the
reticuloendothelial system. The principle mode of excretion
in mice appears primarily to be through the urine, 90% of
the injected dose being excreted within ﬁve days after injec-
tion. This quick excretion rate causes large drug concentra-
tion ﬂuctuations in the body, and hence, also unpredictable
therapeutic activity, a highly undesirable situation. The neg-
ative impact of such drug concentration ﬂuctuations in the
body becomes apparent when one relates it to 50% lethal
dosages (LD50 values), optimum dosages, and a dosage hav-
ing no inﬂuence on the diseased site at all. For cisplatin [8],
the LD50 dosage applicable to mice is 14mg/kg mass of test
animal,theoptimum dose is halfofthis,7mg/kgtestanimal,
but 3mg/kg mass of the test animal has absolutely no inﬂu-
ence on the diseased site at all. With the excretion proﬁle that
cisplatin shows, it is clear that it is extraordinary diﬃcult to
maintain drug levels in a patient close to the optimum dose
level, but still below the LD50 value for prolonged times. The
initial required overdose of drug that is required to maintain
useful drug levels in the body explains much of the negative
side eﬀects of chemotherapeutic drugs.
A further point of consideration in developing and ad-
ministering anticancer drugs is the development of drug re-
sistance by a tumour after prolonged use. A neoplastic pop-
ulation of cells is not a static entity, but rather an ever-
changing one. Tumours display an amazing ability to es-
cape or neutralize the actions of chemotherapeutic agents to
which they were initially sensitive [9]. Some common exam-
ples of this evasive ability are as follows [10]:
(a) the loss of speciﬁc receptors;
(b) down-regulation of tumour-associated antigens; and
(c) shedding of antigens into the body ﬂuids.
The metastatic nature of cancer cells thus leads to the de-
velopment of drug resistance after continued drug dosage
[11, 12].
One of the most fundamental barriers to selective drug
delivery involves the so-called targeting problem. The cen-
tral problem of cancer chemotherapy remains one of selec-
tive drug action. Ideally, one would like a toxic agent that
can discriminate between neoplastic and nonneoplastic cells.
This approach presumes the existence of something to aim
at, that is, some molecular characteristic that diﬀers between
target and nontarget cells. The metastatic nature of cancer
cells makes this a formidable task. Even if a target can be
identiﬁed,oracellneedcanbeexploited,ashasbeendonein
vitro, the problem remains of actually bringing the pharma-
ceutical agent, in vivo, from the point of administering to the
neoplastic growth. To achieve this, many physiological barri-
ers including the reticuloendothelial system of the body have
to be bypassed.
Consequently, to improve the treatment of cancer, re-
search today focusses on developing new and better chemo-
therapeutic agents having less side eﬀects (i.e., drugs that can
zoom onto diseased sites) [13], new methods of drug deliv-
ery are being researched [6], combination therapy is being
investigatedinthehopeofﬁndingsynergisticeﬀects[14],the
scope of radiation therapy is broadened, and completely new
methods of combating cancer are sought.
New metal-based drugs include members of the ti-
tanocene and ferrocene family of compounds [13, 15]. A
promising example of a new method of cancer treatment fo-
cussesonphotodynamictherapy(PDT)[16,17].InPDT,the
photo-active drugs in themselves are inactive towards both
healthy and cancer cells. However, when light of the cor-
rect wavelength is shone on them, the drugs become photo-
activated and give rise to conditions that kill the cells it is
in contact with, normally via the generation of singlet oxy-
gen. A good measure of selective cancer cell killing is there-
fore induced into the treatment of a patient merely by fo-
cussing light from a suitable laser source onto a tumourous
growth. Healthy cells will stay largely undamaged provided
that light is not shone upon it. If cancer cells would selec-
tively and preferentially absorb the PDT drug, this would
leadtoafurtherenhancementofselectivecancercelldestruc-
tion. Phthalocyanines and related macrocycles are second-
generation PDT agents. Many phthalocyanine derivatives
havetheadvantageofbeingpreferentiallyabsorbedbycancer
cells. Some of them were found to be distributed upto 90%
selectively in cancer cells, and only 10% in healthy cells after
a certain induction period [18].
3. SYNTHETIC POLYMERIC DRUG DELIVERY SYSTEMS
Many detrimental properties and side eﬀects of promising
anticancer drugs may at least be partially overcome if the
pharmaceutical agent is covalently anchored to a polymeric
drug carrier. Polymeric or macromolecular drug-carrying
devices should be distinguished from sustained drug-release
systems. Sustained drug-release systems are normally asso-
ciated with polymers; frequently insoluble; and in the form
of powders, pellets, and capsules from which the slow re-
lease of an encapsulated drug from the “container” interior
is possible. They normally do not represent systems that may
aﬀect target-speciﬁc drug delivery as much as they are de-
vicesforthecontinuedreleaseofdrugs.Theterm“polymeric
drug carrier” describes a polymer or macromolecule that
contains covalent binding sites that are available to anchor
active pharmaceutical units as terminal or pendent groupsM. David Maree et al. 3
protruding from the side of the polymeric chain. Polymeric
drug-carrying devices may be synthetic or naturally occur-
ring.Thenaturallyoccurringonessuchasantibodies[19,20]
induce a high mode of selective drug action onto the poly-
meric drug-containing device, but usually suﬀer from a lack
oflargeamountsofdrug-anchoringsites.Syntheticpolymers
on the other hand are more prone to suﬀer from immuno-
genic side eﬀects [21], but this may be overcome by copoly-
merisation with ethylene glycol fragments. Their big advan-
tage is that they can be tailor-made to be suitable for almost
any purposes and can be engineered to have a large amount
of drug-anchoring sites.
The clinical administration of a polymer bound drug, as
compared to the free agent, may signiﬁcantly enhance the
therapeutic eﬀectiveness in terms of the following:
(a) accelerated and unencumbered distribution in the
aqueous central circulation system of the body (the
blood), thereby reducing the risks of premature degra-
dation and excretion;
(b) they facilitate cell entry via endocytosis—a cell mem-
brane penetration mechanism generally unavailable
to nonpolymeric compounds but highly desired for
drugs operating intracellularly;
(c) more precisely controlled drug serum levels (i.e., the
restriction of the drug concentration to the gap be-
tween toxic and minimum eﬀective levels);
(d) an enhanced depot eﬀect through slow drug release
from the polymer-drug conjugate.
The structural features of the polymer-drug conjugate re-
quired to comply with these attributes include the following:
(a) a highly ﬂexible linear main chain comprising struc-
tural entities that can provide water solubility;
(b) asuﬃcientlylargemolecularmasstopreventquickex-
cretion from the body (the threshold for elimination
via the kidneys is ca. 70000g mol
−1);
(c) a biodegradable carrier backbone prone to catabolic
elimination of the “spent” polymer main chain after
the payload of drug has been delivered to the target
site;
(d) alargeamountofreactivefunctionalgroupsassuitable
binding sites for drug attachment, these sites should
be distanced from the main chain by short (5–15 con-
stituent atoms) spacer segments to diminish the steric
bulk eﬀect of the polymeric carrier backbone, and
they should be suﬃciently separated from each other
along the backbone to prevent intramolecular multi-
functional drug binding;
(e) the separation of binding sites on the polymeric back-
bone requires insertion of side chains on the main
chain between active binding sites that lack drug-
bindingcapabilities,butenhanceotherdesirableprop-
erties. These may include enhancing the hydrophilic
nature of the ultimate polymeric drug-carrying de-
vice, the incorporation of moieties that enhance drug-
targetingcapability(i.e.,atumourhomingdevice),an-
tispasmodic properties, or any other desirable physio-
logical eﬀect;
(f) one or more bioﬁssionable functions (amide, ester,
urethane, disulphide, etc.) to be inserted into the
carrier-drugconnectinglink.Atleastoneofthesemust
be suﬃciently remote from the main chain to permit
enzymeapproachandcleavageactiontoresultineﬀec-
tive drug release in a targeted biological compartment;
(g) carrier backbones and spacers which are non toxic
per se. They should especially possess absolute mini-
mal immunogenicity so as to preclude carrier-induced
pathological eﬀects. This means polymeric drug-
carrying devices should be completely biocompatible.
Akey component towards the success of polymeric drug-
carrying devices centres around biodegradable bonds and
their capability to home preferentially onto a neoplastic
growth. Apart from targeting ﬂeeting receptors on a col-
lection of metastatic neoplastic cells, the nutritional needs
of such cells may be utilized to gain preferential neoplastic
cell access. Neoplastic cells grow much faster than healthy
cells, and have a much higher demand for food in the
form of amino acids and energy. Hence copolymers con-
structed at least partially from amino acids are very attrac-
t i v ea sp o l y m e r i cd r u gd e l i v e r yd e v i c e s .T h e ya l s oi n t r o d u c e
the biodegradable amide (peptide) bond. Other degradable
bonds include nucleotide and sugar bonds. Sugar groups as
a source of energy will especially enhance preferential uptake
by neoplastic cells. Other biodegradable groups that may be
employed include disulphide bonds that may be reduced to
thiol groups [22], or, since cell interior has a lower pH than
blood plasma, for example, weakly acid-labile groups such as
thio-ethers [23].
4. SYNTHETIC STRATEGIES TOWARDS POLYMERIC
DRUG DELIVERY SYSTEMS
Although models as those mentioned above for synthetic
polymeric drug carriers have been in existence for some time
[24], until recently only a few eﬀorts were made to actually
prepare such compounds. A review by Neuse [25] describes
some of the most recent researches in this ﬁeld. Scheme
1 illustrates the synthetic approach to actually obtain such
polymeric drug-delivering devices. The centre of Scheme 1
serves to visualise the overall strategy. At the left and right
ends of Scheme 1 an example for an actual synthesis of a
polymeric drug delivery system [26] is highlighted next to
each colour-coded step of the general strategy. The use of
the water-soluble polyaspartic acid drug carrier not only al-
lowed the water-insoluble parent ferrocene-containing drug
to be well soluble in water in concentrations exceeding 100g
dm
−3 but it also increased the cytotoxicity of the active drug
as tested on murine EMT-6 cancer cells from an LD90 value
of 500μg/cm−3 in the case of free 3-ferrocenylbutanoic acid
to 80μg/cm−3 drug content for the polymeric drug delivery
device [27].
At least two factors probably contribute to the enhanced
activity of the above-mentioned polymeric drug delivery de-
vice. The ﬁrst must be related to the enhanced aqueous solu-
bility of the ferrocene drug. Free ferrocene itself, which is in-
soluble in water, has been shown to be completely inactive as4 Metal-Based Drugs
cytotoxic agent. The second factor centres around the use of
aspartic acid as monomeric subunit in the main chain of the
polymeric drug carrier. As the cancer cells have a large need
fornutrientssuchasaminoacids,theuseofapolyaminoacid
as drug carrier may cause the drug carrying device to be ab-
sorbed faster and more eﬃciently by cancer cells than would
be the case for the free drug.
Akeyfactorshouldbeobservedinthesyntheticsequence
showninScheme1.Thegeneralstrategyinthemiddleshows
the use of difunctional monomers. Aspartic acid is trifunc-
tional. The use of tri- or higher-functional polymerization
monomers is useful in the synthesis of polymeric drug carri-
ers,asitprovidesafreearmwherethedrugmayeventuallybe
anchored.Onlytwoofthethreeormoremonomerfunction-
alities should be used to obtain a linear, highly ﬂexible, and
soluble monomer. The other functional group(s) ultimately
will provide drug attachment sites. However, normally the
useoftri-orhigher-functionalisedmonomerswillleadtothe
formation of highly crosslinked, rigid, and insoluble poly-
mers.Inthecaseofasparticacid,thisdidnothappenbecause
the formation of stable ﬁve-membered succinimide rings is
thermodynamicallyhighlyfavoured.Iteﬀectivelymaskedthe
secondcarboxylicacidfunctionalgroupofasparticacidfrom
unwanted crosslinking reactions. For other tri- or higher-
functionalized amino acids, such as trifunctionalised lysine
or tetrafunctionalised cystine [22], protection of the addi-
tional functional groups is required to prevent formation of
pharmaceutically undesired crosslinked polymers.
5. MECHANISMOFCELLUPTAKEANDDRUGRELEASE
Uptake by neoplastic (and healthy) cells of the soluble poly-
meric device, shown in Scheme 1,p r o b a b l yo c c u r sb ye n d o -
cytosis, in particular, by ﬂuid-phase pinocytosis as described
by Duncan and Kopeˇ cek [6]. As shown in Figure 1,p o l ym e r s
in solution are internalised by means of ﬂuid-phase pinocy-
tosis. Cell internalisation may also occur if the polymeric
drug delivery device binds to surface cell receptors by means
of adsorptive pinocytosis. They are then internalized as at-
tachments to the infolding membrane. Polymeric drug car-
riers with porphyrins or phthalocyanines attached to them
will probably gain access to neoplastic cells by means of ad-
sorptive pinocytosis as this would be consistent with the se-
lective uptake of these macrocycles by cancer cells. Mixtures
of ﬂuid-phase and adsorptive pinocytosis may also occur. It
was found that pinocytotic uptake by cells of polymers bear-
ingphenol-containingsidechainswasgreatlyenhanced[28].
Onceinternalized, fusionofthepinocytotic vesicleswithpri-
mary lysosomes takes place to form secondary lysosomes.
Release of the drug from the polymeric drug carrier inside
the secondary lysosomes occurs by enzymatic hydrolysis of
the biodegradable amide bonds that link the drug, ferrocene
in Scheme 1, with the polymeric drug carrier, a polyaspar-
tic acid derivative in Scheme 2. Primary lysosomes may con-
tain more than 50 hydrolytic enzymes that are generated in
the Golgi apparatus. Next, the drug and other useful low-
molecular-mass degradation products like amino acids are
released from the secondary lysosomes for use inside the cell
nucleous. Finally, the “spent” polymer main chain and any
other nondegradable material leave the cell by exocytosis.
A key factor emerges from this discussion. According to
this mechanism, no drug is released outside a living cell be-
cause these drugs are not in contact with appropriate hy-
drolytic enzymes. As the folding pattern of the polymeric
drug carrier normally inactivates the drug while polymer-
bound, it means no negative side eﬀects can be induced by
the drug prior to release from the polymeric main chain. In
addition, if the polymeric drug delivery device could be de-
signed in such a way that it is internalized selectively into
only neoplastic cells, the negative side eﬀects associated with
chemotherapy could be circumvented completely.
6. THE SYNTHESES OF LYSINE-BASED POLYMERIC
DRUG CARRIERS
Lysine, 1, introduces a new dimension into our discussion of
the design of polymeric drug carriers. To prevent crosslink-
ing reactions, one of the three lysine functional groups has to
beprotected.Herewechoosetoprotectanaminogroup.One
can either protect the α- or the ε-amino group, Scheme 2,t o
obtain lysine derivatives 3 or 4, respectively. Only α-amino
triﬂuoroacetyl protected lysine, 3, is obtained by direct treat-
ment of lysine with triﬂuoroacetic anhydride in triﬂuo-
roacetic acid because the ε-amino group is much more basic
than the α-amino group [29]. The zwitter-ionic structure of
lysine,1,impliesthattheε-aminogroupismainlyinthepro-
tonated form and thus well protected against acylation reac-
tions. However, treatment of 1 with ethyl thioltriﬂuoroacte-
tate under basic conditions [30] according to the method de-
scribed by Schallenberg gave Nε-triﬂuoroacetyllysine, 4,i n
33% yield after recrystallisation from hot water/ethanol in a
2 : 3 ratio. It is advantageous to use the ε-amino group rather
than the α-amino group eventually as the drug-anchoring
site because it separates it far enough from the polymer
main chain to allow easy enzyme approach to initiate cleav-
age of amide bonds to facilitate drug release from the even-
tual drug-carrying devices 11–13. If the α-amino group is
protected for later drug-anchoring purposes, the steric bulk
eﬀect of the polymeric main chain may be so large that
enzyme-induced drug release will become kinetically very
slow. In addition, it was also previously demonstrated [26]
that drug-anchoring reactions of the type shown in Scheme
2 to generate 11–13 via amide bond formation proceed more
eﬀectively with compounds possessing longer side chains.
We describe here the syntheses, from Nε-trifluoroacetyll-
ysine 4, aspartic acid 5,a n dp o l y m e r i cp r e c u r s o r s6 and 7 of
polymeric drug carriers 8 and 9,S c h e m e2. We also describe
how the ferrocenyl and phthalocyanine moieties may be co-
valently anchored to the carrier polymers 8 and 9 utilising
the coupling agent 10 to obtain the polymeric drug delivery
devices 11, 12,a n d13.
It was not very easy to predetermine reaction condi-
tions to obtain a speciﬁc target x/y ratio in polymer 6 be-
cause of a tendency towards homopolymerisation by aspar-
tic acid. In ﬁrst experiments, 4 and 5 were thermally copoly-
merised in a monomer mole ratio of 1:10 (4:5) at 180
◦C
under nitrogen and atmospheric pressure in the presenceM. David Maree et al. 5
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Scheme 1: Main picture: Colour-coded general synthetic strategy towards the syntheses of polymeric drug carrier devices. Right, in blue:
functionalisation of the antineoplastic drug, ferrocene, to 3-ferrocenylbutanoic acid. Left: The synthesis of a speciﬁc ferrocene-containing
drug delivery device derived from aspartic acid. The colour codes in the side portions are the same as those used in the central main picture.
Themainpicturewasreproducedwithpermissionfromcopyrightowner“InternationalUnionofPureandAppliedChemistry.”Anadaption
of the main part of this scheme was previously published as follows: J. C. Swarts, in Macromol. Sym., Eds. K. Levon and A. Guiseppi-Elie),
vol 186, pages 123–128, 2002; Copyright Wiley-VCH Verlag GmbH & Co. KgaA, reproduced with permission.
of a polyphosphoric acid (PPA) mass fraction of 0.8 for 8
hours. Two products were isolated. The ﬁrst was extracted
with water, and after dialysis in an 8,000 molecular mass cut-
oﬀ membrane tubing, 6 was isolated having an x/y = 2.6/1
ratio, and inherent viscosity ηinh = 0.06dl g−1 in 3% yield,
m.p = 301
◦C (dec.). The x/y ratio was established by com-
paring the 1H NMR signal integrals at 5.1–5.5ppm (CH of
imide, one proton per closed imide unit), 4.4–4.6ppm (CH
of aspartic acid, the integral values showed only 65% ring
closure of the aspartic acid recurring unit occurred), with
that of the combined β, γ,a n dδ methylene protons of the
lysine recurring unit (6 protons per lysine recurring unit) at
0.9–1.8ppm.Theremainingwater-insolubleresiduewasdis-
solved in DMF and precipitated with ethanol to yield 56%
polymer having ηinh(DMF) = 0.07dl g−1,m . p= 286
◦C( d e c . )
In this case, the x/y unit ratio was established by 1HN M Ra s
22/1. The percentage of aspartic acid ring closure was found
tobeca.97%.Theremainderofmaterialhadmolecularmass
<8,000g mol
−1, and was dialysed away.
When 4 and 5 were thermally co-polymerised in a
monomer mole ratio of 1:6 = 4:5, other conditions still be-
ing the same, the water-soluble fraction was isolated in 8%
possessing a monomer ratio of x/y = 1.4/1. The DMF-soluble
fraction wasisolated in 30% yield havinga monomer ratio of
x/y = 25/1. In another experiment, when the PPA mass frac-
tion was lowered from 0.8 to 0.5, the water-soluble fraction
was very small, but the DMF-soluble fraction was isolated in
50% yield having also a monomer ratio of x/y = 25/1.
The above results showed that 4 and 5 have a tendency
to homopolymerise. The low lysine content in each recov-
eredfractionwasattributedtothetendencyofα-aminoacids
to form 6-membered diketopiperazine rings upon heating
[31]. In the case of 4, this would result in termination of any
polymerisation process, and account also for the large % of
low-molecular-massmaterialthatwaslostupondialyses. 13C
NMRspectroscopyshowedthatthetriﬂuoroacetylprotective
group did not survive the polymerisation conditions. How-
ever, loss of the triﬂuoroacetyl protective group must have
happened in the latter stages of polymerisation, since no in-
soluble portion was found in the workup of 6. Crosslinking
was, therefore, ruled out as the cause of the relatively moder-
ate yields.
Further experiments focussed exclusively on a 1:2 = 4:5
monomer mole ratio in a PPA mass fraction of 0.5 at 180
◦C
for only 2.5 hours at pressures below 2torr. These conditions
resulted in almost no water-soluble fraction (<1%), and a
DMF-soluble fraction (18% yield, decomposition tempera-
ture = 269
◦C) having a repeating unit ratio of x/y = 7/1 and
29% of aspartic acid fragments still uncyclised. 13CN M R
showed that the triﬂuoroacetyl protective group remained
intact when using these shorter reaction times. By substitut-
ing PPA with 85% ortho H3PO4, repeated experiments gave6 Metal-Based Drugs
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Figure 1: Mechanism of drug uptake and release inside cells. Diagram reproduced with permission from copyright owner “International
Union of Pure and Applied Chemistry.” It was previously published as follows: J. C. Swarts, in Macromol. Sym., Eds. K. Levon and A.
Guiseppi-Elie), vol 186, p123–128, 2002; Copyright Wiley-VCH Verlag GmbH & Co. KgaA, reproduced with permission.
productshavingrecurringunitratiosranging2/1<x/y <5/1.
Yields were slightly higher (25%). The increase in yield and
better recurring unit ratios probably arose because it is eas-
ier to mix 4 and 5 to a homogeneous distribution in ortho
H3PO4 t h a ni nP P A .L o w e rr e a c t i o nt e m p e r a t u r e s( 1 4 0
◦C)
lowered yields substantially to only 6% and virtually the en-
tire product became water-soluble, even after 7 hours of re-
action time. Dialyses were again performed in 8,000 molec-
ular mass membrane tubing. The absence of any 1HN M R
signals at 5.25ppm, as well as the presence of the signal at
4.2–4.6ppm showed that for this product, ring closure of the
aspartic acid fragment did not occur. It had a repeating unit
ratio of x/y = 4/1 as compared to the target of 2/1. 13CN M R
showed that the triﬂuoroacetyl protective group remained
intactundertheseconditionsofdecreasedtemperatureseven
though the reaction time was increased to 7 hours.
Nucleophilic attack of amines on the succinimide rings
of polymeric precursor 6 takes place with ease, and the suc-
cess rate is independent of x/y ratios. By choosing the cor-
rect nucleophiles, the solubility properties of choice may be
introduced to the carrier polymer. Here, the 3-aminopropyl
morpholine unit was used to generate water-soluble 8 in
83% yield after stirring the intermediate product 7 with
2% NaOH solution to remove the triﬂuoroacetyl protecting
group and dialysis in 8,000 molecular mass cutoﬀ membrane
tubing. Although intermediate 7 can be isolated en route to
8, this is not necessary. One can go directly from 6 to 8 with-
out isolation of 7. 2-Phenylethyl amine was used to generate
white, water-insoluble 9 in 90% yield after removal of the
protective group and slow precipitation with water from a
DMF solution.
To demonstrate the carrier capabilities of 8 and 9, the
antineoplastic ferrocenyl moiety [15] and an example of the
family of drugs that may be used in photodynamic can-
cer therapy [17], a phthalocyanine, have been anchored on
these polymeric drug carriers. Both ferrocene and phthalo-
cyanine are insoluble in water when not functionalised, or
as carboxylic acid derivatives. Even as sodium carboxylates,
they are poorly soluble in water. However, once anchored
on the polymeric drug carrier 8, the ferrocene-containing
derivative 11 was soluble in excess of 30g/dm
3, while the
phthalocyanine derivative exceeded an aqueous solubility of
ca. 5g dm
−3 at pH’s more extreme than those found in the
gastrointestinal system (1–8.5) [32, 33]. However, prior to
druganchoring,theferroceneandphthalocyaninefragments
needed to be modiﬁed in such a way that coupling with the
available amine active sites on the polymeric drug carriers
8 and 9 is possible. To generate a biodegradable bond be-
tween drug and polymeric carrier, formation of a peptide
(i.e., amide), saccharide, or nucleotide bonds [34]i sd e s i r -
able. Here, the amide bond was aimed for as a biodegradable
bondlinkingcarriertodrug.Thus,3-ferrocenylbutanoicacid
[35] and cobaltotetracarboxyphthalocyanine [36]w e r ep r e -
pared according to known procedures for later reaction with
the amine-containing polymeric carrier devices 8 and 9.
Although polymers 8 and 9, the ferrocene-containing
derivatives 11 and 13, and the phthalocyanine-contain-
ing derivative 12 are robust, frequently the drug moiety ofM. David Maree et al. 7
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Scheme 2: Syntheses of polymeric drug carrying devices 11, 12 (M = Co), and 13. For PDT applications, M = Zn or Cl–Al would be more
appropriate [18]. All polymers have a random recurring unit arrangement in the backbone. The indicated structures are meant to show
building block ratios rather than block polymers. Opening of the succinimide rings of 6 with nucleophiles R1-NH2 lead to a mixture of α
and β ring-opened aspartates. For convenience, only the α-form is shown.
interest (as opposed to the drug carrier) may be very labile.
It is advantageous, therefore, to be able to anchor the drug
onto the polymeric carrying device under very mild con-
ditions in order to preserve labile moieties. Also, coupling
procedures need to be developed that will allow coupling in
media in which both the water-soluble drug carrier, here 8
and 9, and poorly soluble or aqueous-insoluble drug may be
partially dissolved or suspended. Coupling with the aid of
O-benzotriazolyl-N,N,N ,N -tetramethyluronium hexaﬂuo-
rophosphate, 10,a tr o o mt e m p e r a t u r e i nD M Fo rD M S O ,
sometimes with THF or water as cosolvent, satisﬁes this re-
quirement [26]. 24-hour reactions between tetracarboxyph-
thalocyanine and 8 with a x/y ratio of 3/1 in the presence of
this coupling agent led to only ca. 10% phthalocyanine bind-
ing in 12 as ascertained by 1H NMR utilising the phthalocya-
nine phenyl aromatic proton signal (12 hours per phthalo-
cyanine group) at ca. 7.3ppm and the –CH2–O–CH2 mor-
pholine signals (4 hours per morpholine group) at 3.6ppm.
This result means z = 0.1y.
The closeness of the COOH functional group in the ph-
thalocyanine moiety had two eﬀects, both associated with
an extremely slow coupling rate due to the closeness of the
bulky phthalocyanine core (slow coupling reactions because
of steric crowding have already been commented on, and
are described in reference 25). Firstly, it explains the low
binding eﬃciency (z = 0.1y) of cobaltotetracarboxyphthalo-
cyanine to polymeric drug carrier 8. Secondly, it explains
why crosslinking reactions involving cobaltotetracarboxyph-
thalocyanine apparently did not take place to a noticeable
extent. As ascertained by 1H NMR, no precipitate from the
dialysis tubing other than free cobaltotetracarboxyphthalo-
cyanine (i.e., unbound) could be found.
In contrast, 3-ferrocenylbutanoic acid was anchored to a
derivativeof 8havingax/y ratioof2/1ca.70–80%eﬀectively
(i.e., zaverage = 0.75y) within 1 hour at room temperature to
give11asproduct.Thisresultwasobtainedbycomparing 1H
NMR signals (obtained in D2O) of the –CH2–O–CH2 mor-
pholine signals (4 hours per morpholine group) at 3.53ppm8 Metal-Based Drugs
with those of the CH3 substituent in 3-ferrocenylbutanoic
acidat1.1ppm(itis awell-deﬁnedpeakthatcanbe uniquely
identiﬁed next to the lysine signals), the combined β, γ,a n d
δ methylene protons of the lysine recurring unit (6 protons
per lysine recurring unit) at 1.2–1.6ppm, and the aspartate
CH protons at 4.2–4.5ppm. An atomic absorption iron ele-
mental analysis for 11 with x/y = 2 / 1s h o w e da ni r o nc o n t e n t
of 4.8% which corresponds to z = 0.67y. CHN elemental
analyses were not performed.
Coupling of 3-ferrocenylbutanoic acid to a derivative of
9 with x/y ratio 3/1 to obtain 13 in DMF as solvent was
moresuccessful,probablybecausetherewasnosolventwater
present during the coupling reaction, see experimental. By
comparing the integral values of the phenyl group 1HN M R
signals (in DMSO-d6−x) at 7.15ppm with those of the CH3
substituent in 3-ferrocenylbutanoic acid at 1.2ppm (it is a
well-deﬁnedpeakthatcanbeuniquelyidentiﬁedbetweenthe
lysine signals) and the combined β, γ,a n dδ methylene pro-
tons of the lysine recurring unit (6 protons per lysine recur-
ring unit) at 0.9–1.6ppm, it was ascertained that the ferro-
cenyl group was anchored 94% eﬃciently, that is, z = 0.94y.
An atomic absorption iron elemental analysis for 13 with x/y
= 3/1 showed an iron content of 5.08% which corresponds to
z = 0.87y. CHN elemental analyses were not performed.
The water-insoluble polymer 12 is of particular interest
becauseitdemonstratestwoseparatefunctionalmoietiescan
be supported on the same polymer drug carrier, here phenyl
and ferrocenyl. This begs the question: “can more than one
antineoplastic group be anchored on the same polymeric
drug carrier?” If this would be possible, combination therapy
wouldbepossiblewithoutadministeringmorethanonetype
of drug in separate doses to a patient. The synergistic eﬀect
usually associated with combination therapy [36, 37]w o u l d
then be potentially obtainable in a single drug dose by bind-
ing to the carrier polymer all the drugs required. This topic is
at present being researched. Biological studies are at the mo-
ment in progress to determine if present lysine-containing
polymeric drug-carrying devices 11 and 12 can compare in
eﬃciency with previously described polyaspartic acid drug-
delivering systems [26].
7. EXPERIMENTAL
Equipmentandmaterials
All organic solvents were distilled prior to use, water was
double-distilled. Chemicals were from Merck & CO., Inc.
(NJ,USA)orSigma-Aldrichandusedwithoutfurtherpuriﬁ-
cation.Meltingpointsareuncorrected.NMRmeasurements,
at 298K, were recorded on a Bruker Advance DPX 300 NMR
spectrometer. Chemical shifts are reported as δ values rela-
tive to SiMe4 at 0ppm. Infrared spectra were recorded on a
Hitachi 270–50 infrared spectrometer in a KBr matrix. Vis-
cosity measurements were made in a Cannon-Fenske tube
at 35.2
◦C in water or DMF. Dialysis was performed in 8,000
molecularmasscutoﬀcellulosemembranetubing.Ironanal-
yseswereperformedonaVarianTechtronatomicabsorption
spectrometer at 272nm.
Syntheses
Nε-triﬂuoroacetyllysine, 4,[ 30] and cobalto tetracarboxyph-
thalocynanine [36] were prepared as described before.
A representative example of the synthesis of polymer
6: Aspartic acid (1.331g; 10mmol), Nε-triﬂuoroacetyllysine
(1.211g; 5mmol), and polyphosphoric acid (2.542g) were
thoroughly mixed in a 250cm3 round-bottom ﬂask. The
ﬂask was mounted on a rotating evaporator, and lowered
(while rotating slowly) into an oil bath preheated to 180
◦.
The pressure was reduced after 5 minutes to below 2 torr
with the aid of a mechanical pump. After 2.5 hours of slow
rotation the reaction mixture was allowed to cool and thor-
oughly extracted with water. Dialyses of the water extract for
16 hours gave after freeze drying only a negligible quantity
of product. The remaining residue after water extraction was
dissolved in 20cm3 DMF. Precipitation by ethanol aﬀorded
0.38 g (18%) of 6; ηinh(DMF) = 0.08dl g−1, x/y = 7/1 (see
discussion text for conditions to obtain other x/y ratios);
m.p. 295
◦C (dec.). 1H NMR (DMSO-d6-x): 0.9–1.8 (6H; β,
γ and δ CH2’s of lysine); 2.1 (3.8 H; CH2 of open aspartic
acid fragment); 2.6–2.9 (4.8 H; CH of succinimide); 3.0–3.4
(4.8 H; CH of succinimide); 4.4–4.6 (1.9 H; CH of aspar-
tic acid fragment); 5.1–5.5 (4.8 H; CH of succinimide). 13C
NMR (DMSO-d6-x): 110–122, q, CF3; 155-156, q, COCF3.
IR: 1798, 1720 (C=O); 1219, 1189 (CF3).
Polymers 7,a n d9: A solution of 0.21 g [0.5mmol, ηinh =
0.08dl g−1, x/y = 3/1] of 6 and 2-phenylethyl amine (0.202g;
2mmol) in 5cm3 DMF was stirred for 5 hours at ambient
temperature. The newly formed 7 was not isolated (although
it can be by precipitation with ethanol or water), but stirred
f o r5h o u r sw i t h2 0 c m 3 of a 2% NaOH solution. The re-
sulting clear reaction mixture was dialysed for 16 hours, and
freeze dried to give 0.24g (90% yield) of 9 as a white solid
which would not redissolve in pure water, but was soluble
in DMSO and DMF; ηinh(DMF) = 0.07dl g−1; x/y = 3; m.p
275
◦C (dec.).
Polymer 8: This polymer was obtained in exactly the
samewayaspolymer9,butbyreplacing2-phenylethylamine
with 3-aminopropyl morpholine (0.289g; 2mmol), and the
x/y ratio of 6 was 2/1. Characterisation data for 8 :y i e l d=
83%; ηinh = 0.06dl g−1; x/y = 2; m.p. 196
◦C (dec.). Unlike 9,
this polymer remained water-soluble after dialysis and freeze
drying.
Polymer 11: To a solution of 0.2g (0.24mmol; ηinh
= 0.06dl g−1; x/y = 2) of 8 in 1cm3 water was added
(in the correct order) 0.035g (0.35mmol) triethylamine, a
solution of 0.068g (0.25mmol) 3-ferrocenylbutanoic acid
in 1cm3 THF (the THF may be replaced with DMF)
and 0.114g (0.3mmol) of O-benzotriazolyl-N,N,N ,N -
tetramethyluronium hexaﬂuorophosphate, 10. The mixture
was stirred for one hour at room temperature during
which time the heterogeneous mixture homogenized. Water
(10cm3)wasaddedtothereactionmixturebeforeitwascen-
trifuged,dialysedfor16hoursinan8,000molecularmascut-
oﬀ membrane tubing and freeze dried to give 0.11g (44%) of
11; ηinh = 0.04dl g−1; x : y : z = 2.00:0.35:0.65; m.p. 88
◦C,
dec. at 105
◦C; Fe anal. 4.8% (req. 4.8% for z = 0.65y). 1H
NMR (D2O): 1.0–1.2 (0.65 of 3H, CH3); 1.2–1.6 (6H; β, γM. David Maree et al. 9
and δ CH2’s of lysine); 3.53 (8H, CH2–O–CH2 of morpho-
line), 3.9–4.2 (0.65 of 9H, C10H9Fe); 4.2–4.6 (3H, CH of as-
partate). IR/cm−1: 1660 (C=O); 1550 (NH).
Polymer 12: The same procedure was used as for 11 ex-
cept that the solvents were all DMF, 3-ferrocenylbutanoic
acid was replaced with an equivalent amount of cobalto
tetracarboxyphthalocyanine and the reaction time was in-
creased to 24 hours. Characterisation data: 44% yield; ηinh
= 0.04dl g−1; x : y : z = 2.0:0.9:0.1; m.p. 194
◦C (dec.);
1HN M R( D 2O): 1.2–1.6 (6H; β, γ and δ CH2’s of lysine);
3.53 (8H, CH2–O–CH2 of morpholine); 4.2–4.6 (3H, CH of
aspartate) 7.3–8.3 (0.1 of 12H, phthalocyanine aromatics);
IR/cm−1: 1720, 1660 (C=O); 1550 (NH).
Polymer 13: The same procedure was used as for 12,
except that 8 w a sr e p l a c e db ya ne q u i v a l e n ta m o u n to f9,
tetracarboxyphthalocyanine was replaced with a solution of
0.068 g (0.25mmol) 3-ferrocenylbutanoic acid dissolved in
1cm 3 DMF and the reaction was allowed to proceed for 1
hour only. Characterisation data: 64% yield; ηinh = 0.04dl
g−1; x : y : z = 3.00:0.13:0.87; m.p. 180
◦C (dec.); Fe anal.
5.1% (req. 5.1% for z = 0.87y. 1H NMR (DMSO-d6-x): 1.2
(0.87 of 3H, CH3); 0.9–1.6 (6H; β, γ and δ CH2’s of lysine);
4.1-4.2(0.87of9H,C10H9Fe);4.2–4.6(4H,CHofaspartate).
7.1–7.3 (15 H, C6H5). IR/cm−1: 1655 (C=O); 1553 (NH).
8. CONCLUSIONS
In summary, it was shown that upon using the ther-
mal polymerisation technique, aspartic acid and Nε-
triﬂuoroacetyllysine both have a tendency to homopoly-
merise. This tendency becomes stronger as reaction condi-
tions become harsher, such as higher temperatures, longer
reaction times, or lowering of pressures. Less harsh condi-
tions diminish the tendency to homopolymerisation but also
reduce yields. Ring closure of the aspartic acid fragment be-
comes progressively less eﬃcient when milder reaction con-
ditions are employed. It was also shown that the triﬂuo-
roacetyl protective group is less stable at elevated temper-
atures for prolonged periods of time. Chemical removal of
the triﬂuoroacetyl protective group was achieved under mild
alkaline conditions to liberate free amino groups on side
chains of lysine-containing potential polymeric drug carri-
ers. Coupling of a carboxylic acid-functionalised ferrocene
with the amine-containing polymeric drug carrier was
eﬀectively achieved utilising O-benzotriazolyl-N,N,N ,N -
tetramethyluroniumhexaﬂuorophosphateascouplingagent.
Coupling reactions were more eﬃcient in the absence of wa-
terascosolvent.Couplingofcobaltotetracarboxyphthalocya-
nine was much less successful. This was presumably due to
the poor solubility of cobaltotetracarboxyphthalocyanine in
the required solvents.
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